




WWCOiT im. M. Kopernika w Łodzi
e-mail: misztalmon@gmail.com
Monika Misztal1, Magdalena Krakowska1 , Monika Ryś-Bednarska1, Mariusz Śliwa1,  
Piotr Potemski1, 2
1Copernicus Memorial Multidisciplinary Centre for Oncology and Traumatology, Lodz, Poland
2Chemotherapy Clinic, Oncology Department, Medical University of Lodz, Poland
Symptoms of nervous system damage 
in a patient undergoing anti-PD1 
immunotherapy
ABSTRACT
Symptoms of nervous system damage during immunotherapy with anti-PD1 antibodies occur in approximately 
6% of patients. The most commonly reported neurological adverse reactions are Guillain-Barre syndrome, poly-
neuropathy, demyelinating diseases, myasthenia gravis, and encephalitis.
In the presented patient with disseminated skin melanoma, after four administrations of nivolumab, paraesthesia 
hindering walking and weakness of the lower limbs appeared. Based on Doppler ultrasound, venous thrombosis 
was excluded. Computed tomography of the head did not show metastases or signs of intracranial ischaemia or 
bleeding. The patient was consulted neurologically several times. Steroid therapy, gabapentin, duloxetine, and 
painkillers were used. Despite the temporary improvement due to implemented treatment, the patient died. No 
definitive diagnosis could be made, but the symptoms suggest Guillain-Barre syndrome.
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Introduction
Immunotherapy with checkpoint inhibitors is 
a valuable treatment for various cancers. With the more 
frequent use of this group of drugs, the frequency of 
observed side effects also increases. They result from 
excessive stimulation of the immune system. The most 
common symptoms affect the skin, digestive system, 
endocrine organs, and lungs. Neurological disorders and 
myocarditis are less commonly diagnosed [1]. Nervous 
system side effects affect approximately 6% of patients 
treated with anti-PD1 antibodies. The most commonly 
described are: Guillain-Barre syndrome, polyneuropa-
thy, demyelinating diseases, myasthenia gravis, and 
encephalitis. Symptoms usually appear between 6 and 
13 weeks of treatment [2]. The following is a description 
of a skin melanoma patient who experienced neurotoxic-
ity symptoms during nivolumab treatment.
Case report
In May 2018, a 68-year-old patient diagnosed with 
melanoma of the chest skin with metastases to the right 
axillar and lung lymph nodes, without a mutation in the 
BRAF V600 codon, began treatment with nivolumab 
at the Chemotherapy Clinic in Lodz. The patient was 
in a good general condition, did not report any com-
plaints, and denied any comorbidities. The physical 
examination revealed a 7-cm ulcerative skin tumour of 
the sternal area.
In July, after four antibody administrations, the 
patient reported paraesthesia in the lower extremities 
not responding to painkillers, and weakness in the right 
lower limb, which hindered walking. In laboratory tests 
and ultrasound Doppler of the lower limbs performed 
at that time, no abnormalities could be found that could 
explain the reported symptoms. Due to the severity of 
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the symptoms, nivolumab treatment was discontinued 
and steroid therapy with prednisone 1 mg/kg was started, 
resulting in temporary improvement.
In August, the patient reported worsening of pain. 
Computed tomography of the head excluded metastases 
to the central nervous system, ischaemic stroke, and 
bleeding were. To assess the effectiveness of treatment, 
computed tomography of the chest, abdomen, and pelvis 
was performed, which showed the progression of the 
disease in the lungs and lymph nodes; the picture of the 
remaining organs remained normal. The patient was 
consulted neurologically, but apart from a slight paresis 
of the right lower limb, no abnormalities were found. Ac-
cording to the neurologist’s recommendations, magnetic 
resonance imaging of the lumbosacral spine was planned 
and gabapentin and duloxetine were added. The pred-
nisone dose was also increased to 2 mg/kg. The drugs 
used once again allowed for a short-term improvement.
The ailments intensified again in September 
2018. The man could barely get up from a chair. In ad-
dition, paraesthesia occurred in the upper limbs. The 
patient was referred to the neurological ward in which 
he died on October 1, 2018.
Discussion
Guillain-Barré syndrome is an acquired periph-
eral nerve disease of autoimmune aetiology. The main 
symptoms are paraesthesia and progressive paresis with 
abolition or weakness of deep reflexes. These ailments 
are usually of an ascending nature and are characterised 
by rapid growth over several days or weeks. The diag-
nosis is based on the clinical picture and abnormalities 
in EMG (slowdown in conduction in the peripheral 
nerves) and cerebrospinal fluid test results (character-
istic increase in protein concentration with normal cell 
number). Clinical signs usually precede the changes 
seen in EMG. In severe cases, with possible biting and 
swallowing disorders as well as respiratory and circula-
tory abnormalities, the treatment consists of securing 
basic life functions. Other patients use plasmapheresis 
or intravenous immunoglobulin preparations [3]. In the 
case of idiopathic Guillain-Barré syndrome, the use of 
glucocorticosteroids is not recommended; however, 
1–2 mg/kg of prednisone is indicated in Guillain-Barré 
syndrome caused by anti-PD1 antibodies [2].
The wide spectrum of side effects of immunotherapy 
is a challenge for clinicians. In this patient, the symptoms 
were differentiated from a neurological disease not re-
lated to cancer and treatment, paraneoplastic syndrome, 
venous thrombosis, stroke, and disease progression in 
the form of central nervous system metastases. Despite 
the neurological consultation, no diagnosis could be 
established. As recommended, steroid therapy was used. 
These symptoms suggest Guillain-Barré syndrome.
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